secwatch.observer — SEC 8-K summary
======================================

Issuer:     Augmedix, Inc. (—)
CIK:        0001769804
Form:       8-K
Filed at:   2024-10-02T23:59:59+00:00
Accession:  0001193125-24-230765
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.03, 5.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Commure completes acquisition of Augmedix for $2.35/share; stock delisted
-------------------------------------------------------------------------

- Merger completed Oct 2, 2024; Augmedix stockholders receive $2.35 per share in cash.
- Total consideration payable to equityholders approximately $139 million, funded by equity and cash.
- Augmedix becomes wholly owned subsidiary of Commure; common stock delisted from Nasdaq.
- All outstanding warrants terminated for no consideration; loan agreement repaid in full.
- Entire board resigned; Tanay Tandon named CEO, Daniel Brian CFO/Secretary of surviving company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/0001193125-24-230765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1769804/000119312524230765/d875756d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-230765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer